查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1842164

日本自体免疫疾病诊断市场：市场规模、份额、趋势分析（按检测项目、产品、检测类型和最终用途划分）、细分市场预测（2025-2033 年）

Japan Autoimmune Disease Diagnostics Market Size, Share & Trends Analysis Report By Test (Systemic Autoimmune Disease Diagnostics, Localized Autoimmune Disease Diagnostics), By Product, By Test Type, By End Use, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

市场规模与趋势：

据估计，2024年日本自体免疫疾病诊断市值为3.6549亿美元，预计到2033年将达到6.4045亿美元，2025年至2033年的复合年增长率为6.6%。

作为全球老化速度最快的国家，日本65岁及以上人口占比超过29%，面临着类风湿性关节炎和自体免疫胰臟炎等疾病日益严重的挑战。这推动了对抗核抗体（ANA）检测、抗体组合和先进分子检测的需求。此外，多重免疫测量、人工智慧和生物标记发现等领域的技术创新，以及产学研合作的加强，也为市场成长提供了支持。例如，Sysmex、MBL和Autobio Diagnostics之间的伙伴关係，提高了检测的准确性、扩充性和早期疾病检测能力。

根据内务部（2023年10月）的数据，日本人口为1.2435亿，比前一年减少59.5万人（-0.48%），连续第13年下降。其中男性人口为6,049万人（-0.44%），女性人口为6,386万人（-0.51%）。男性人口自然下降的趋势已持续19年，女性人口自然下降的趋势已持续15年，反映出人口持续减少的现状。然而，净移民趋势以及外国居住人口的稳定增长在一定程度上抵消了人口下降的影响，日本国民净移民数量三年来首次转正。

这些人口趋势直接影响自体免疫疾病诊断市场。例如，类风湿性关节炎（RA）在日本影响约82.2万人（牛津大学出版社，2024年5月），其发病高峰年龄在65至85岁之间。由于RA在老年族群中较为常见，因此，随着人口老化，对诊断服务的需求也随之增长，尤其是抗核抗体（ANA）检测、抗体组合和确证性分子检测。

目录

第一章：日本自体免疫疾病诊断市场：调查方法与范围

第二章：日本自体免疫疾病诊断市场：执行摘要

  • 市场概况
  • 按类型和产品分类的简介
  • 按测试类型和最终用途分類的简介
  • 竞争格局概览

第三章：日本自体免疫疾病诊断市场：影响因素、趋势与范围

  • 市场区隔及范围
  • 市场关联性展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
  • 市场驱动因素分析
    • 对早期、非侵入性诊断的需求日益增长
    • 技术进步
    • 产学合作
  • 市场限制因素分析
    • 高昂的费用和有限的报销
  • 市场机会分析
    • 个人化医疗和基于生物标记的检测的扩展
  • 波特五力分析
  • PESTLE分析

第四章：日本自体免疫疾病诊断市场：按类型分類的估算与趋势分析

  • 日本自体免疫疾病诊断市场：波动分析（按类型划分）
  • 系统性自体免疫疾病诊断
    • 类风湿性关节炎
    • 僵直性脊椎炎的诊断
    • 全身性红斑性狼疮（SLE）
    • 其他的
  • 局部自体免疫疾病诊断
    • 多发性硬化症
    • 1型糖尿病
    • 桥本氏症
    • 特发性血小板减少紫斑症
    • 其他的

第五章：日本自体免疫疾病诊断市场：按产品分類的估算与趋势分析

  • 日本自体免疫疾病诊断市场：波动分析（依产品分类）
  • 装置
  • 耗材和检测
  • 基于质谱的分析

第六章：日本自体免疫疾病诊断市场：按检测类型分類的估算与趋势分析

  • 日本自体免疫疾病诊断市场：按检测类型分類的波动分析
  • 抗核抗体检测
    • 间接萤光(IIF) 抗核抗体 (ANA) 检测
    • 基于ELISA的ANA检测
    • 多重/多联免疫检测抗核抗体（ANA）检测组
    • 其他的
  • 自体抗体检测
    • 类风湿因子（RF）检测
    • 抗环瓜氨酸肽（抗CCP）检测
    • 抗双股DNA检测
    • 抗史密斯（Sm）抗体检测
    • 抗Ro/SSA和抗La/SSB抗体检测
    • 其他的
  • C反应蛋白（CRP）
  • 全血球计数（CBC）
  • 尿液检查
  • 其他的

第七章：日本自体免疫疾病诊断市场：终端用户估算与趋势分析

  • 日本自体免疫疾病诊断市场：依最终用途分類的波动分析
  • 医院
  • 诊断中心
    • 收入估算与预测（2021-2033 年）
  • 其他的

第八章 竞争情势

  • 公司分类
  • 策略规划
    • 新产品上市
    • 伙伴关係
    • 企业收购
    • 商业合作
    • 资金筹措
  • 主要企业市占率分析（2024 年）
  • 公司热力图分析
  • 公司简介
    • Fujirebio
    • SEKISUI MEDICAL CO., LTD
    • Medical &Biological Laboratories（MBL）
    • Bio-Rad Laboratories, Inc.
    • Abbott
    • F. Hoffmann-La Roche, Ltd.
    • Siemens Healthineers AG
    • Sysmex Corporation
    • BioMerieux
    • Beckman Coulter（Danaher）
Product Code: GVR-4-68040-738-6

Market Size & Trends:

The Japan autoimmune disease diagnostics market size was estimated at USD 365.49 million in 2024 and is expected to reach USD 640.45 million by 2033, growing at a CAGR of 6.6% from 2025 to 2033. As the world's fastest-aging nation, with over 29% of its population aged 65 or older, Japan faces a rising prevalence of conditions such as rheumatoid arthritis and autoimmune pancreatitis. This fuels demand for ANA tests, autoantibody panels, and advanced molecular assays. Growth is further supported by innovations in multiplex immunoassays, AI, and biomarker discovery, alongside strong academic-industry collaborations. Partnerships, such as those involving Sysmex, MBL, and Autobio Diagnostics, enhance precision, scalability, and early disease detection.

According to the Statistics Bureau of Japan (October 2023), the country's population stood at 124.35 million, down by 595,000 people (-0.48%) from the previous year-marking the thirteenth consecutive annual decline. Male and female populations fell to 60.49 million (-0.44%) and 63.86 million (-0.51%), respectively. Natural population decline has persisted for 19 years among men and 15 years among women, reflecting ongoing demographic contraction. However, net migration trends offered some offset, with positive net migration among Japanese citizens for the first time in three years, alongside steady growth in the foreign resident population.

This demographic backdrop directly influences the autoimmune disease diagnostics market. Rheumatoid arthritis (RA), for instance, affects an estimated 822,000 people in Japan (Oxford University Press, May 2024), with peak prevalence among individuals aged 65-85. Given its higher occurrence in older adults, RA illustrates how aging demographics are driving demand for diagnostic services-particularly ANA tests, autoantibody panels, and confirmatory molecular assays.

Japan Autoimmune Disease Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the Japan autoimmune disease diagnostics market based on type, product, test type, and end use:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Systemic autoimmune disease diagnostics
    • Rheumatoid arthritis
    • Ankylosing spondylitis diagnostics
    • Systemic lupus erythematosus (SLE)
    • Others
  • Localized autoimmune disease diagnostics
    • Multiple sclerosis
    • Type 1 diabetes
    • Hashimoto's Thyroiditis
    • Idiopathic thrombocytopenic purpura
    • Others
  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Instruments
  • Consumables & Assays
  • Test Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Antinuclear antibody tests
    • Indirect Immunofluorescence (IIF) ANA tests
    • ELISA-based ANA tests
    • Multiplex/line immunoassay ANA panels
    • Others
  • Autoantibody tests
    • Rheumatoid Factor (RF) tests
    • Anti-Cyclic Citrullinated Peptide (Anti-CCP) tests
    • Anti-dsDNA tests
    • Anti-Smith (Sm) antibody tests
    • Anti-Ro/SSA & Anti-La/SSB antibody tests
    • Others
  • C-reactive Protein (CRP)
  • Complete blood count (CBC)
  • Urinalysis
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Diagnostic Centers
  • Others

Table of Contents

Chapter 1. Japan Autoimmune Disease Diagnostics Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Type Segment
      • 1.1.1.2. Technology Segment
      • 1.1.1.3. End Use Segment
  • 1.2. Estimates and Forecast Timeline
  • 1.3. Objectives
    • 1.3.1. Objective - 1
    • 1.3.2. Objective - 2
    • 1.3.3. Objective - 3
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information or Data Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Validation
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. List of Abbreviations

Chapter 2. Japan Autoimmune Disease Diagnostics Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Type and Product Snapshot
  • 2.3. Test Type and End Use Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Japan Autoimmune Disease Diagnostics Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Rising demand for early and non-invasive diagnosis
    • 3.4.2. Technological advancements
    • 3.4.3. Academic-industry collaborations
  • 3.5. Market Restraint Analysis
    • 3.5.1. High cost and limited reimbursement coverage
  • 3.6. Market Opportunity Analysis
    • 3.6.1. Expansion of personalized medicine and biomarker-based testing
  • 3.7. Porter's Five Forces Analysis
  • 3.8. PESTLE Analysis

Chapter 4. Japan Autoimmune Disease Diagnostics Market: Type Estimates & Trend Analysis

  • 4.1. Japan Autoimmune Disease Diagnostics Market: Type Movement Analysis
  • 4.2. Systemic autoimmune disease diagnostics
    • 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.2.2. Rheumatoid arthritis
      • 4.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.2.3. Ankylosing spondylitis diagnostics
      • 4.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.2.4. Systemic lupus erythematosus (SLE)
      • 4.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.2.5. Others
      • 4.2.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3. Localized autoimmune disease diagnostics
    • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.2. Multiple sclerosis
      • 4.3.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.3. Type 1 diabetes
      • 4.3.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.4. Hashimoto's Thyroiditis
      • 4.3.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.5. Idiopathic thrombocytopenic purpura
      • 4.3.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.6. Others
      • 4.3.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Japan Autoimmune Disease Diagnostics Market: Product Estimates & Trend Analysis

  • 5.1. Japan Autoimmune Disease Diagnostics Market: Product Movement Analysis
  • 5.2. Instruments
    • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3. Consumables & Assays
    • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Mass spectrometry-based assays

Chapter 6. Japan Autoimmune Disease Diagnostics Market: Test Type Estimates & Trend Analysis

  • 6.1. Japan Autoimmune Disease Diagnostics Market: Test Type Movement Analysis
  • 6.2. Antinuclear antibody tests
    • 6.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.2.2. Indirect Immunofluorescence (IIF) ANA tests
      • 6.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.2.3. ELISA-based ANA tests
      • 6.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.2.4. Multiplex/line immunoassay ANA panels
      • 6.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.2.5. Others
      • 6.2.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3. Autoantibody tests
    • 6.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.2. Rheumatoid Factor (RF) tests
      • 6.3.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.3. Anti-Cyclic Citrullinated Peptide (Anti-CCP) tests
      • 6.3.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.4. Anti-dsDNA tests
      • 6.3.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.5. Anti-Smith (Sm) antibody tests
      • 6.3.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.6. Anti-Ro/SSA & Anti-La/SSB antibody tests
      • 6.3.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.7. Others
      • 6.3.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. C-reactive Protein (CRP)
    • 6.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Complete blood count (CBC)
    • 6.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Urinalysis
    • 6.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Others
    • 6.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Japan Autoimmune Disease Diagnostics Market: End Use Estimates & Trend Analysis

  • 7.1. Japan Autoimmune Disease Diagnostics Market: End Use Movement Analysis
  • 7.2. Hospitals
    • 7.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3. Diagnostic Centers
    • 7.3.1. Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4. Others
    • 7.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
    • 8.2.1. NEW PRODUCT LAUNCH
    • 8.2.2. PARTNERSHIPS
    • 8.2.3. ACQUISITION
    • 8.2.4. COLLABORATION
    • 8.2.5. FUNDING
  • 8.3. Key Company Market Share Analysis, 2024
  • 8.4. Company Heat Map Analysis
  • 8.5. Company Profiles
    • 8.5.1. Fujirebio
    • 8.5.2. SEKISUI MEDICAL CO., LTD
      • 8.5.2.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Medical & Biological Laboratories (MBL)
      • 8.5.3.1. Company Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Bio-Rad Laboratories, Inc.
      • 8.5.4.1. Company Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Abbott
      • 8.5.5.1. Company Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. F. Hoffmann-La Roche, Ltd.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Siemens Healthineers AG
      • 8.5.7.1. Company Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Sysmex Corporation
      • 8.5.8.1. Grifols Company Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. BioMerieux
      • 8.5.9.1. Company Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Beckman Coulter ( Danaher)
      • 8.5.10.1. Company Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List 0f Abbreviation
  • Table 2 Japan Autoimmune Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 3 Japan Autoimmune Disease Diagnostics Market, By Product, 2021 - 2033 (USD Million)
  • Table 4 Japan Autoimmune Disease Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 5 Japan Autoimmune Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market summary
  • Fig. 4 Market segmentation & scope
  • Fig. 5 Market size and growth prospects
  • Fig. 6 Japan autoimmune disease diagnostics market - Key market driver analysis
  • Fig. 7 Japan autoimmune disease diagnostics market - Key market restraint analysis
  • Fig. 8 Penetration & growth prospect mapping
  • Fig. 9 Japan autoimmune disease diagnostics market - Porter's analysis
  • Fig. 10 Japan autoimmune disease diagnostics market - PESTEL analysis
  • Fig. 11 Japan autoimmune disease diagnostics market Type outlook key takeaways
  • Fig. 12 Japan autoimmune disease diagnostics market : Type movement analysis
  • Fig. 13 Systemic autoimmune disease diagnostics market estimates, 2021 - 2033 (USD Million)
  • Fig. 14 Rheumatoid arthritis market estimates, 2021 - 2033 (USD Million)
  • Fig. 15 Ankylosing spondylitis diagnostics market estimates, 2021 - 2033 (USD Million)
  • Fig. 16 Localized autoimmune disease diagnostics market estimates, 2021 - 2033 (USD Million)
  • Fig. 17 Multiple sclerosis market estimates, 2021 - 2033 (USD Million)
  • Fig. 18 Type 1 diabetes market estimates, 2021 - 2033 (USD Million)
  • Fig. 19 Hashimoto's Thyroiditis market estimates, 2021 - 2033 (USD Million)
  • Fig. 20 Idiopathic thrombocytopenic purpura market estimates, 2021 - 2033 (USD Million)
  • Fig. 21 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 22 Japan autoimmune disease diagnostics market product outlook key takeaways
  • Fig. 23 Japan autoimmune disease diagnostics market : product movement analysis
  • Fig. 24 Instruments market estimates, 2021 - 2033 (USD Million)
  • Fig. 25 Consumables & Assays market estimates, 2021 - 2033 (USD Million)
  • Fig. 26 Japan autoimmune disease diagnostics market Test type outlook key takeaways
  • Fig. 27 Japan autoimmune disease diagnostics market : Test type movement analysis
  • Fig. 28 Antinuclear antibody tests market estimates, 2021 - 2033 (USD Million)
  • Fig. 29 Indirect Immunofluorescence (IIF) ANA tests market estimates, 2021 - 2033 (USD Million)
  • Fig. 30 ELISA-based ANA tests market estimates, 2021 - 2033 (USD Million)
  • Fig. 31 Multiplex/line immunoassay ANA panels market estimates, 2021 - 2033 (USD Million)
  • Fig. 32 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 33 Autoantibody tests market estimates, 2021 - 2033 (USD Million)
  • Fig. 34 Rheumatoid Factor (RF) tests estimates, 2021 - 2033 (USD Million)
  • Fig. 35 Anti-Cyclic Citrullinated Peptide (Anti-CCP) tests estimates, 2021 - 2033 (USD Million)
  • Fig. 36 Anti-dsDNA tests estimates, 2021 - 2033 (USD Million)
  • Fig. 37 Anti-Smith (Sm) antibody tests estimates, 2021 - 2033 (USD Million)
  • Fig. 38 Anti-Ro/SSA & Anti-La/SSB antibody tests estimates, 2021 - 2033 (USD Million)
  • Fig. 39 Others estimates, 2021 - 2033 (USD Million)
  • Fig. 40 C-reactive Protein (CRP) market estimates, 2021 - 2033 (USD Million)
  • Fig. 41 Complete blood count (CBC) market estimates, 2021 - 2033 (USD Million)
  • Fig. 42 Urinalysis market estimates, 2021 - 2033 (USD Million)
  • Fig. 43 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 44 Japan autoimmune disease diagnostics market end use outlook key takeaways
  • Fig. 45 Japan autoimmune disease diagnostics market : end use movement analysis
  • Fig. 46 Hospitals market estimates, 2021 - 2033 (USD Million)
  • Fig. 47 Diagnostic Centers market estimates, 2021 - 2033 (USD Million)
  • Fig. 48 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 49 Strategy framework